Iorio Di Sold 25,000 Shares of XO Group Inc. (XOXO); Aratana Therapeutics (PETX) Sentiment Is 1.56

Aratana Therapeutics, Inc. (NASDAQ:PETX) Logo

Aratana Therapeutics Inc (PETX) investors sentiment decreased to 1.56 in 2017 Q4. It’s down -0.16, from 1.72 in 2017Q3. The ratio turned negative, as 50 hedge funds started new and increased equity positions, while 32 cut down and sold positions in Aratana Therapeutics Inc. The hedge funds in our database now own: 30.34 million shares, down from 31.53 million shares in 2017Q3. Also, the number of hedge funds holding Aratana Therapeutics Inc in top ten equity positions decreased from 2 to 1 for a decrease of 1. Sold All: 13 Reduced: 19 Increased: 29 New Position: 21.

XO Group Inc. provides multiplatform media and marketplace services to the wedding, pregnancy and parenting, nesting, and local entertainment markets. The company has market cap of $686.86 million. The firm operates a network of Websites under various brands, such as The Knot, which offers wedding resources and marketplaces through wedding Website and mobile apps, national and local wedding magazines, and nationally published books; and The Bump, a pregnancy and parenting brand that provides personalized information, content, and tools for navigating the journey from fertility to pregnancy and parenting through the toddler years. It has a 124 P/E ratio. The Company’s network of Websites also include The Nest, which focuses on nesters setting up homes and navigating new lives together; and GigMasters, an event marketplace for finding and booking the entertainment and vendors for birthday parties, weddings, anniversaries, corporate events, and others.

More news for XO Group Inc. (NYSE:XOXO) were recently published by: Seekingalpha.com, which released: “XO Group’s (XOXO) CEO Mike Steib on Q1 2018 Results – Earnings Call Transcript” on May 02, 2018. Globenewswire.com‘s article titled: “New Research: Key Drivers of Growth for SecureWorks, Ingles Markets, Insys Therapeutics, Energous, XO Group, and ..” and published on May 02, 2018 is yet another important article.

Iorio Di is the Chief Technology Officer of Xo Group Inc. He recently made a sale of 25,000 shares in the Pinksheet-listed Xo Group Inc with the transaction value amounting to about $562,500 U.S. Dollars. That is according to the filing documented price of $22.5 per every share. This stocks unloading decreased his ownership of the company to 0.55% market capitalization or 139,062 shares.

Analysts await XO Group Inc. (NYSE:XOXO) to report earnings on May, 8. They expect $0.02 earnings per share, up 100.00% or $0.01 from last year’s $0.01 per share. XOXO’s profit will be $503,560 for 341.00 P/E if the $0.02 EPS becomes a reality. After $0.14 actual earnings per share reported by XO Group Inc. for the previous quarter, Wall Street now forecasts -85.71% negative EPS growth.

Since March 7, 2018, it had 0 buys, and 2 insider sales for $5.72 million activity. 5,000 shares valued at $103,078 were sold by Di Iorio Nic on Wednesday, March 7. Another trade for 275,465 shares valued at $5.61M was sold by LIU DAVID.

Investors sentiment increased to 1.1 in Q4 2017. Its up 0.14, from 0.96 in 2017Q3. It increased, as 7 investors sold XO Group Inc. shares while 45 reduced holdings. 14 funds opened positions while 43 raised stakes. 21.68 million shares or 0.81% more from 21.51 million shares in 2017Q3 were reported. Comerica Bancshares has 24,921 shares for 0% of their portfolio. Meeder Asset Management Inc has 1,953 shares. Royal National Bank & Trust Of Canada holds 0% of its portfolio in XO Group Inc. (NYSE:XOXO) for 43,809 shares. Principal Grp holds 0% or 181,921 shares in its portfolio. Legal & General Grp Public Limited Co reported 44,909 shares. Texas Permanent School Fund has 0% invested in XO Group Inc. (NYSE:XOXO). New York-based Blackrock has invested 0% in XO Group Inc. (NYSE:XOXO). Strs Ohio holds 0% of its portfolio in XO Group Inc. (NYSE:XOXO) for 39,400 shares. Geode Capital Ltd Liability Corporation invested in 246,150 shares. Teton Inc holds 0.13% of its portfolio in XO Group Inc. (NYSE:XOXO) for 74,991 shares. Mufg Americas Holdg Corporation reported 214 shares. Boston Prtn reported 0% of its portfolio in XO Group Inc. (NYSE:XOXO). Goldman Sachs Grp Inc reported 0% stake. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment Management Corp owns 0% invested in XO Group Inc. (NYSE:XOXO) for 21,400 shares. Guggenheim Capital Ltd Liability Co holds 0% in XO Group Inc. (NYSE:XOXO) or 90,254 shares.

Among 6 analysts covering XO Group (NYSE:XOXO), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. XO Group has $25 highest and $16.75 lowest target. $20.42’s average target is -25.15% below currents $27.28 stock price. XO Group had 12 analyst reports since December 6, 2016 according to SRatingsIntel. The stock has “Neutral” rating by Roth Capital on Thursday, October 12. The stock has “Buy” rating by Sidoti on Friday, December 16. The rating was initiated by Aegis Capital on Tuesday, December 6 with “Buy”. Stifel Nicolaus downgraded XO Group Inc. (NYSE:XOXO) on Wednesday, March 1 to “Hold” rating. The firm earned “Hold” rating on Tuesday, October 31 by Roth Capital. The firm has “Buy” rating given on Monday, March 5 by Aegis Capital. The rating was upgraded by FBR Capital to “Buy” on Thursday, May 3. Roth Capital maintained XO Group Inc. (NYSE:XOXO) rating on Thursday, March 1. Roth Capital has “Hold” rating and $19.75 target. The rating was maintained by Roth Capital on Tuesday, August 1 with “Buy”.

The stock increased 2.90% or $0.77 during the last trading session, reaching $27.28. About 273,758 shares traded or 90.44% up from the average. XO Group Inc. (NYSE:XOXO) has risen 20.11% since May 5, 2017 and is uptrending. It has outperformed by 8.56% the S&P500.

Since January 1, 0001, it had 0 buys, and 3 insider sales for $307,923 activity.

The stock increased 0.40% or $0.02 during the last trading session, reaching $5.07. About 660,184 shares traded or 42.36% up from the average. Aratana Therapeutics, Inc. (PETX) has declined 14.71% since May 5, 2017 and is downtrending. It has underperformed by 26.26% the S&P500.

Broadfin Capital Llc holds 3.69% of its portfolio in Aratana Therapeutics, Inc. for 4.29 million shares. Awm Investment Company Inc. owns 1.48 million shares or 1.51% of their US portfolio. Moreover, General American Investors Co Inc has 0.57% invested in the company for 1.12 million shares. The Massachusetts-based Mpm Asset Management Llc has invested 0.53% in the stock. Grandeur Peak Global Advisors Llc, a Us-based fund reported 538,363 shares.

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. The company has market cap of $237.50 million. The Company’s product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. It currently has negative earnings. The firm markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs.

More important recent Aratana Therapeutics, Inc. (NASDAQ:PETX) news were published by: Seekingalpha.com which released: “Aratana’s (PETX) CEO Steven St. Peter on Q1 2018 Results – Earnings Call Transcript” on May 04, 2018, also Benzinga.com published article titled: “Benzinga’s Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down”, Globenewswire.com published: “Recent Analysis Shows Waterstone Financial, Blue Bird, Proto Labs, American Assets Trust, MoSys, and Aratana …” on May 02, 2018. More interesting news about Aratana Therapeutics, Inc. (NASDAQ:PETX) was released by: Benzinga.com and their article: “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” with publication date: April 29, 2018.

XO Group Inc. (NYSE:XOXO) Institutional Positions Chart